Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2019 - 2026)

Zentalis Pharmaceuticals has reported Cash & Equivalents for 8 years, with the latest figure at $31.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 23.85% year-over-year to $31.9 million; the trailing twelve-month figure through Mar 2026 stood at $31.9 million (down 23.85% YoY), and the FY2025 full-year result was $36.0 million, up 6.18% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $31.9 million, down from $36.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $266.6 million in Q2 2023, with the low at $28.0 million in Q4 2023.
• Average Cash & Equivalents over 5 years is $55.8 million, with a median of $37.6 million recorded in 2024.
• Year-over-year, Cash & Equivalents surged 383.39% in 2023 and sank 86.13% in 2024.
• Tracing ZNTL's Cash & Equivalents over 5 years: stood at $43.1 million in 2022, then sank by 34.9% to $28.0 million in 2023, then climbed by 20.91% to $33.9 million in 2024, then grew by 6.18% to $36.0 million in 2025, then dropped by 11.29% to $31.9 million in 2026.
• The last three Cash & Equivalents figures came in at $31.9 million (Q1 2026), $36.0 million (Q4 2025), and $39.1 million (Q3 2025), per Business Quant data.

Peer Comparison